Welcome to our dedicated page for IMMNOV news (Ticker: IMMNOV), a resource for investors and traders seeking the latest updates and insights on IMMNOV stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IMMNOV's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IMMNOV's position in the market.
Immunovia (IMMNOV), a pancreatic cancer diagnostics company, announced a webcast scheduled for December 17, 2024, at 3 pm CET to discuss the positive clinical validation results of their next-generation pancreatic cancer test, which were published on December 9, 2024.
The webcast will feature presentations from key company executives including CEO Jeff Borcherding, VP Clinical and Medical Affairs Dr. Norma Alonzo Palma, and Laboratory Director Dr. Lisa Ford. Dr. Aimee Lucas, Chief of Gastroenterology & Hepatology at Mount Sinai, will provide additional perspective on the study outcomes.
The company focuses on developing blood-based testing for early pancreatic cancer detection, targeting the US market where an estimated 1.8 million individuals are at high risk and could benefit from annual surveillance testing.
Immunovia (NASDAQ Stockholm: IMMNOV) will present results from its recently completed model-development study of their next-generation pancreatic cancer detection test at the 2024 annual meeting of the Collaborative Group of Americas—Inherited Gastrointestinal Cancers (CGA-IGC). The company's abstract was accepted and recognized for inclusion in the Henry Lynch Lecture. Immunovia is currently conducting a clinical validation study of its next-generation test, expected to complete in December 2024, with plans to launch the test in 2025. The company estimates that in the USA, 1.8 million individuals at high-risk for pancreatic cancer could benefit from annual surveillance testing.
Immunovia will present updates on its next-generation pancreatic cancer detection test at the annual PRECEDE Consortium meeting. The test showed 85% sensitivity and 98% specificity in a model-development study of 623 patient samples. The PRECEDE Consortium, comprising 51 pancreatic centers worldwide, aims to increase five-year survival rates to 50% through early detection research. The consortium has enrolled over 7,000 of its targeted 10,000 high-risk patients. Immunovia plans to complete clinical validation in December 2024 and launch the test in 2025.
Immunovia (IMMNOV: Nasdaq Stockholm) has successfully acquired all blood samples needed to clinically validate its next-generation test for pancreatic cancer. The company has secured over 1,000 blood samples, including 200+ from early-stage pancreatic cancer patients and 800+ from high-risk individuals without cancer. This marks a key milestone towards completing one of the largest clinical validation studies of a pancreatic cancer biomarker test to date.
The study aims to confirm the sensitivity and specificity of Immunovia's new test in differentiating early-stage pancreatic cancer samples from those without cancer. Collaborators include researchers from the University of Pittsburgh, Oregon Health and Science University, University of Verona, and the Pancreatic Cancer Early Detection (PRECEDE) Consortium. Immunovia expects to complete the study in December 2024 and launch the test later in 2025.
Immunovia (IMMNOV: Nasdaq Stockholm) has completed the analytical validation of its next-generation test for early-stage pancreatic cancer detection. The validation demonstrated excellent results across 23 key performance attributes, meeting CLIA and CAP accreditation standards. Key highlights include high precision, linearity, sensitivity, stability, and robustness. The test uses an automated ELISA analyzer, enhancing performance and throughput compared to previous methods.
Following this success, Immunovia has initiated a large-scale clinical validation study to assess the test's accuracy in detecting stage 1 and 2 pancreatic cancer, expected to be completed by December 2024. This study will provide important insights into the test's clinical performance, including sensitivity and specificity.
Immunovia (IMMNOV: Nasdaq Stockholm) presented results from its model development study for a next-generation pancreatic cancer detection test at the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer. The study, involving 623 patient samples, demonstrated the test's superior performance with 85% sensitivity and 98% specificity. Notably, the test's sensitivity surpassed that of CA19-9, a common pancreatic cancer biomarker, by 20 percentage points.
The presentation detailed the biomarker selection process, algorithm construction, and test performance. Immunovia's VP of Clinical and Medical Affairs, Norma Palma PhD, emphasized the importance of scientific review and data dissemination for driving adoption of the test, which is slated for launch next year.
Immunovia (Nasdaq Stockholm: IMMNOV) has filed a US provisional patent application for its next-generation test to detect stage 1 and 2 pancreatic cancer. The application covers methods of diagnosing pancreatic ductal adenocarcinoma (PDAC) using a unique combination of five specific biomarkers. The company plans to submit additional clinical data to strengthen the application and file a PCT application within a year for international protection.
Immunovia aims to launch the new test in the US market in 2025, following a large, independent clinical validation study in Q4 2024. The company estimates that 1.8 million individuals in the USA are at high risk for pancreatic cancer and could benefit from annual surveillance testing.
Immunovia (IMMNOV) has completed development of its next-generation pancreatic cancer detection test, achieving 85% sensitivity and 98% specificity in detecting stage 1 and 2 pancreatic ductal adenocarcinomas (PDAC). The test outperformed CA19-9, a common pancreatic cancer biomarker, by 20 percentage points. In patients aged 65 and older, the test achieved 91% sensitivity and 98% specificity. The study included 624 patient samples from 13 clinical sites. Immunovia plans to launch the test in the U.S. in 2025, following a large, independent clinical validation study in Q4 2024. The company estimates that 1.8 million high-risk individuals in the USA could benefit from annual surveillance testing.
Immunovia (Nasdaq Stockholm: IMMNOV) presented detailed discovery study results for its next-generation early detection test for pancreatic cancer at the PancreasFest 2024 Annual Meeting. The study, the most comprehensive pancreatic cancer proteomics study to date, identified 15 promising protein biomarkers that strongly correlate with pancreatic ductal adenocarcinoma (PDAC). Over 3,000 proteins were evaluated in 329 blood samples from Stage I and II PDAC and non-PDAC matched control patients using Olink multiplex technology and conventional immunoassays. The biomarkers demonstrated the ability to differentiate PDAC cases from non-PDAC controls. This presentation reflects the initial positive data shared in a November 7, 2023 press release.
Immunovia (NASDAQ: IMMNOV) has announced that its new lab in Research Triangle Park, USA, is now fully operational and staffed. The lab, focused on early detection of pancreatic cancer, was occupied on May 21, 2024, and all necessary equipment has been installed and validated. Two new scientists have been hired, and the team will validate assays developed with Proteomedix on an ELISA platform. The lab will conduct a clinical validation study of the next-generation test in Q4 2024. Immunovia has also filed to transfer its CLIA license and renew its CAP accreditation.
